Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05270863 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy Study BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic or Pseudophakic Presbyopia
A Phase 3 study, sponsored by Visus Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 182
- Enrollment target
NCT05270863 is a Phase 3 study that has completed, run by Visus Therapeutics. The registered enrollment target is 182 participants.
The verdict
NCT05270863, a Phase 3 study, has completed, sponsored by Visus Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 182 participants
- Enrollment target
Study Summary
Safety and Efficacy Study of BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic and Pseudophakic Presbyopia
Interventions
- DRUG BRIMOCHOL™ PF
- DRUG Carbachol PF
- DRUG Brimonidine tartrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 182 participants |
| Start Date | 2022-03-30 |
| Est. Completion | 2023-04-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05270863
The ClinicalTrials.gov registry entry for NCT05270863 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 182 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Visus Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which BRIMOCHOL™ PF is the first listed.
NCT05270863 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05270863 about?
NCT05270863 is a clinical study titled "Safety and Efficacy Study BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic or Pseudophakic Presbyopia". Safety and Efficacy Study of BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic and Pseudophakic Presbyopia
What is the current status of trial NCT05270863?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 182 participants. The study started on 2022-03-30. Estimated completion is 2023-04-10.
What interventions are being tested in trial NCT05270863?
The interventions under investigation include: BRIMOCHOL™ PF (DRUG), Carbachol PF (DRUG), Brimonidine tartrate (DRUG).
Who is sponsoring clinical trial NCT05270863?
This trial is sponsored by Visus Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.